Moogene Medi

Moogene Medi is a South Korean biotechnology company specializing in advanced drug delivery systems that integrate lipid nanoparticles (LNPs) with ultrasound technology. The company's core platform, often referred to as sonoporation, utilizes microbubbles and ultrasound to enhance the transdermal and targeted delivery of various therapeutic payloads, including CRISPR/Cas9 gene-editing tools, proteins, and small molecules. Their lead candidate, HUTERA, is a topical formulation of dutasteride for androgenetic alopecia designed to maximize local efficacy while minimizing systemic side effects. Moogene Medi is also developing gene therapies for oncology indications such as colorectal and pancreatic cancer, leveraging their LNP technology to overcome drug resistance.